Zantac Lawsuit: Settlements, Dismissals and Appeals (2026)

What the Case Was About and Why It Began

Zantac was a popular heartburn and acid reflux drug made with ranitidine. In September 2019, the FDA warned the public about NDMA found in ranitidine samples. The agency classifies NDMA as a probable human carcinogen, meaning lab results suggest it could cause cancer. Days later, Sandoz started the first voluntary recall of ranitidine capsules.

Further testing showed that NDMA levels in some ranitidine products climbed over time and when the drug was stored above room temperature. That finding pushed the FDA to request a full market withdrawal in April 2020, which ended ranitidine sales in the United States.

People who took Zantac for years and later developed cancer began filing suits. Each Zantac lawsuit accused the drugmakers of hiding the cancer risk from patients and doctors. In federal court, the claims centered on five "Designated Cancers" – bladder, esophageal, gastric (stomach), liver and pancreatic cancer.

Who Was Sued

In February 2020, the Judicial Panel on Multidistrict Litigation sent the federal Zantac cases to Judge Robin L. Rosenberg in the Southern District of Florida. This multidistrict litigation, or MDL, groups similar cases before one judge so pretrial work happens once instead of hundreds of times.

The panel named six common defendants: Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline LLC, Pfizer Inc., Sanofi-Aventis U.S. LLC, Sanofi US Services Inc. and Chattem, Inc. Each had made, sold or distributed Zantac at some point.

How the Federal MDL Fell Apart

The federal cases collapsed at the science stage. Before any trial, a judge decides whether expert witnesses used reliable methods. In a 341-page order, Judge Rosenberg found that plaintiffs' general causation experts – the witnesses who would say ranitidine can cause cancer at all – did not meet that standard. Without them, the drugmakers won summary judgment, a ruling that ends a case without a trial.

GSK's second-quarter 2026 report states that about 14,000 product liability cases were dismissed after that order. Plaintiffs appealed to the U.S. Court of Appeals for the Eleventh Circuit, and the company expects a decision in the second half of 2026.

The order covered only the five Designated Cancers, so cases involving other cancers were not part of it. That helps explain why the MDL remains technically open, with 847 actions still pending as of September 1, 2026.

State Court Trials and the Delaware Collapse

With federal claims stalled, the fight moved to state courts, where judges apply their own rules. The first Zantac case to reach a jury ended on May 23, 2024, when a Cook County, Illinois, panel rejected Angela Valadez's claim that the drug caused her colon cancer. She had sought $640 million from GSK and Boehringer Ingelheim.

Plaintiffs kept losing. By the August 2025 verdict in the Jeffrey Halter case, Boehringer Ingelheim had either won or seen a deadlocked jury in eight Zantac trials.

Delaware held the biggest docket, with nearly 75,000 plaintiffs. A trial judge first let their experts testify in May 2024. The Delaware Supreme Court reversed that decision in July 2025, holding that the lower court had used a standard that leaned toward admitting expert testimony. When plaintiffs then asked to bring in new expert reports, the trial court said no.

The final blow came in April 2026. Judge Francis J. Jones, Jr. ruled that proof the drug can cause cancer is a required part of every plaintiff's case and granted summary judgment on all complaints filed on or before December 1, 2025. The decision ended more than 80,000 suits against Boehringer Ingelheim. According to GSK, plaintiffs filed a notice of appeal on May 13, 2026.

Zantac Settlements and Payouts

Most of the money in the Zantac litigation came from settlements, not verdicts. GSK's October 2024 deal with 10 plaintiff firms covered about 93% of its state court product liability cases. GSK admitted no liability and expected the deal to be fully in place by mid-2025. It also agreed to pay $70 million to resolve a separate qui tam complaint – a fraud claim brought on the government's behalf – filed by Valisure.

Pfizer's May 2024 agreement resolved more than 10,000 state court cases. The terms were not public at first, but a Financial Times report later put the payout between $200 million and $250 million. Sanofi had already settled about 4,000 cases for more than $100 million, and Pfizer resolved two more Connecticut cases in September 2025 without disclosing terms.

Individual payouts under these deals stayed confidential. A separate investor lawsuit against GSK over Zantac did not survive either. A court dismissed the securities class action on March 4, 2026, finding the claims were filed too late, and the investors did not appeal.

Filing Deadlines and What Remains Open

Every state sets a statute of limitations – a deadline to file a personal injury lawsuit. In many states, the clock typically starts when a person is diagnosed or reasonably learns the injury may be tied to a product. Because ranitidine left the U.S. market in 2020, many possible claims may already be past those deadlines.

Two appeals could still change the picture. The Eleventh Circuit has not yet ruled on the federal dismissals, and Delaware plaintiffs have appealed the April 2026 ruling. Unless one of those courts reverses, the Zantac cancer litigation is largely over, with settlements paid and most remaining claims dismissed.